FDA Issues Final Guidance for ANDA Amendments Under GDUFA II

International Pharmaceutical Regulatory Monitor
A A
The FDA released final guidance spelling out its review goals for amendments to abbreviated new drug applications and prior approval supplements under GDUFA II.

To View This Article:

Login

Subscribe To International Pharmaceutical Regulatory Monitor